| NCT01212484 | Familial Dysautonomia | Drug: Carbidopa|Drug: Placebo | New York University School of Medicine | Phase 3 | 2009-12-01 | 2016-03-07 |
| NCT00829439 | Angelman Syndrome | Drug: Levodopa/Carbidopa (4:1) | Boston Children鈥檚 Hospital | Phase 1 | 2009-01-01 | 2016-09-29 |
| NCT01399905 | Parkinson's Disease | Drug: carbidopa | Oregon Health and Science University | Phase 2 | 2009-03-01 | 2011-07-21 |
| NCT02486432 | Parkinson's Disease | Drug: Levodopa/Carbidopa (Sinemet) | NeuroDerm Ltd.|Quotient Clinical | Phase 1 | 2015-04-01 | 2015-06-28 |
| NCT00391898 | Parkinson's Disease | Drug: Levodopa/carbidopa/entacapone|Drug: Levodopa/carbidopa | Novartis | Phase 4 | 2006-10-01 | 2011-02-16 |
| NCT00745277 | Parkinson's Disease | Drug: Carbidopa-Levodopa|Drug: Carbidopa- Levodopa | Oregon Health and Science University|Parkinson Disease Research, Education and Clinical Center at Portland VA Hospital|RJG Foundation|Oregon Clinical and Translational Research Institute | Phase 2 | 2008-08-01 | 2012-11-28 |
| NCT01229332 | Parkinson's Disease | Drug: Saline|Drug: Carbidopa | NeuroDerm Ltd. | Phase 1|Phase 2 | 2011-01-01 | 2011-12-04 |
| NCT02553265 | Dysautonomia, Familial|Baroreflex Failure Syndrome | Drug: Carbidopa Low Dose|Other: Placebo|Drug: Carbidopa High Dose | New York University School of Medicine | Phase 2 | 2015-09-01 | 2016-12-28 |
| NCT00099268 | Parkinson's Disease | Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa | Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis | Phase 3 | 2004-09-01 | 2012-04-19 |
| NCT02116465 | Fasted State | Drug: Levodopa Carbidopa immediate release tablets | Desitin Arzneimittel GmbH | Phase 1 | 2014-03-01 | 2014-04-14 |
| NCT00558337 | Parkinson's Disease | Drug: levodopa-carbidopa | Osmotica Pharmaceutical US LLC | Phase 2 | 2007-11-01 | 2009-01-13 |
| NCT00642356 | Parkinson's Disease | Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa | Novartis | Phase 4 | 2008-03-01 | 2011-02-16 |
| NCT00547911 | Parkinson Disease|Multiple System Atrophy|Autonomic Nervous System Diseases | Drug: Droxidopa|Drug: Carbidopa|Drug: Entacapone | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) | Phase 1|Phase 2 | 2007-10-01 | 2014-06-17 |
| NCT03023059 | Age-related Macular Degeneration | Drug: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet | Snyder, Robert W., M.D., Ph.D., P.C. | Phase 2 | 2017-03-01 | 2017-01-17 |
| NCT01736176 | Advanced Parkinson's Disease | Drug: Levodopa-Carbidopa Intestinal Gel|Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets | AbbVie (prior sponsor, Abbott)|AbbVie | Phase 3 | 2013-03-01 | 2016-12-16 |
| NCT01323374 | Fibromyalgia | Drug: Droxidopa|Drug: Carbidopa|Drug: Droxidopa/carbidopa|Drug: Placebo | Chelsea Therapeutics | Phase 2 | 2009-01-01 | 2012-07-18 |
| NCT00983814 | Attention Deficit Hyperactivity Disorder | Drug: Droxidopa+Carbidopa|Drug: Placebo | Chelsea Therapeutics | Phase 2 | 2009-10-01 | 2013-03-27 |
| NCT00219284 | Parkinson's Disease With End of Dose "Wearing Off" | Drug: Carbidopa/levodopa/entacapone | Novartis Pharmaceuticals|Novartis | Phase 4 | 2005-01-01 | 2011-02-16 |
| NCT02812394 | Parkinson Disease | Drug: CVT-301 (Dose Level 1)|Drug: CVT-301 (Dose Level 2)|Drug: Sinemet庐 | Acorda Therapeutics | Phase 1 | 2016-06-01 | 2016-10-24 |
| NCT00415740 | Healthy | Drug: ELC200 (carbidopa+levodopa+entacapone) | Novartis | Phase 1 | 2006-05-01 | 2007-06-21 |
